Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 234 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · derivative · entry 7 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,051 Underlying: Common Stock · 234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2019 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2019 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 105 | $238.26 | $25,017.30 |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · nonDerivative · entry 6 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,852 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · nonDerivative · entry 5 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 699 | $238.26 | $166,543.74 |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · nonDerivative · entry 4 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,604 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 2,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · nonDerivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 69 | $238.26 | $16,439.94 |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,950 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · derivative · entry 9 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · derivative · entry 8 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,347 Underlying: Common Stock · 187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 201 | $238.26 | $47,890.26 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · nonDerivative · entry 4 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,127.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · nonDerivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,328.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 62 | $238.26 | $14,772.12 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 20:43 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 109 | $225.85 | $24,617.65 |
DisclosureSEC source: 0001127602-21-004349 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,219.0415 F4 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 30.9407 shares acquired on June 30, 2020 and 36.2220 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 20:40 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 203 | $225.85 | $45,847.55 |
DisclosureSEC source: 0001127602-21-004347 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,152.3789 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:48 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004353 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,348 Underlying: Common Stock · 3,506 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:48 UTC |
Schechter Adam HDirector · President & CEO
|
Tax withholdingCommon Stock | 1,028 | $223.78 | $230,045.84 |
DisclosureSEC source: 0001127602-21-004353 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,288 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:48 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionCommon Stock | 3,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004353 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:46 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004352 · form4.xml · derivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,534 Underlying: Common Stock · 150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:46 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 53 | $223.78 | $11,860.34 |
DisclosureSEC source: 0001127602-21-004352 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523.2194 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 129.2194 shares acquired on June 30, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:46 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004352 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 129.2194 shares acquired on June 30, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:43 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004349 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,167 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:43 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 83 | $223.78 | $18,573.74 |
DisclosureSEC source: 0001127602-21-004349 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,328.0415 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 30.9407 shares acquired on June 30, 2020 and 36.2220 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:43 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004349 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,411.0415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 30.9407 shares acquired on June 30, 2020 and 36.2220 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:40 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004347 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,271 Underlying: Common Stock · 560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:40 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 154 | $223.78 | $34,462.12 |
DisclosureSEC source: 0001127602-21-004347 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,355.3789 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:40 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004347 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,509.3789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:42 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 266 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004348 · form4.xml · derivative · entry 3 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,534 Underlying: Common Stock · 266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:42 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Tax withholdingCommon Stock | 94 | $223.78 | $21,035.32 |
DisclosureSEC source: 0001127602-21-004348 · form4.xml · nonDerivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:42 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionCommon Stock | 266 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004348 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:39 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004346 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,372 Underlying: Common Stock · 560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:39 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 187 | $223.78 | $41,846.86 |
DisclosureSEC source: 0001127602-21-004346 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,071 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:39 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004346 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:36 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 970 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004345 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,956 Underlying: Common Stock · 970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:36 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 306 | $223.78 | $68,476.68 |
DisclosureSEC source: 0001127602-21-004345 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,778 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:36 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004345 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:35 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004344 · form4.xml · derivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,978 Underlying: Common Stock · 560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:35 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 190 | $223.78 | $42,518.20 |
DisclosureSEC source: 0001127602-21-004344 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,651.1697 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 60.0439 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:35 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004344 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,841.1697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 60.0439 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:34 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 373 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004343 · form4.xml · derivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,285 Underlying: Common Stock · 373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:34 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 131 | $223.78 | $29,315.18 |
DisclosureSEC source: 0001127602-21-004343 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,785 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:34 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004343 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:33 UTC |
Seltz Judith CEVP, CHRO
|
Exercise / conversionRestricted Stock Unit · Derivative | 280 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004342 · form4.xml · derivative · entry 3 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220 Underlying: Common Stock · 280 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:33 UTC |
Seltz Judith CEVP, CHRO
|
Tax withholdingCommon Stock | 96 | $223.78 | $21,482.88 |
DisclosureSEC source: 0001127602-21-004342 · form4.xml · nonDerivative · entry 2 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914.9252 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 150.9252 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:33 UTC |
Seltz Judith CEVP, CHRO
|
Exercise / conversionCommon Stock | 280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004342 · form4.xml · nonDerivative · entry 1 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010.9252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 150.9252 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:14 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004338 · form4.xml · derivative · entry 3 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:14 UTC |
BELINGARD JEAN-LUCDirector
|
Tax withholdingCommon Stock | 99 | $223.78 | $22,154.22 |
DisclosureSEC source: 0001127602-21-004338 · form4.xml · nonDerivative · entry 2 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,569 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:14 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004338 · form4.xml · nonDerivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:00 UTC |
Williams R SandersDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004335 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:00 UTC |
Williams R SandersDirector
|
Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004335 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.